| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC11483 | Betrixaban maleate Featured | Betrixaban (PRT-054021) is a highly potent, selective, and orally efficacious factor Xa inhibitor with IC50 of 1.2 nM(inhibition of Factor 10a). |
|
| DC9832 | Betulinic acid Featured | Betulinic acid, a pentacyclic triterpene, selectively induces apoptosis in tumor cells, also is a inhibitor of HIV-1 with EC50 of 1.4 μ M. |
|
| DC23068 | Liquidambaric acid Featured | Betulonic acid has anti-cancer , anti-HIV,hepatoprotective and anti-inflammatory activities, it has antiviral activity against herpes simplex virus, it also suppresses ECHO 6 virus reproduction. |
|
| DC9643 | Bevirimat(PA-457) Featured | Bevirimat(YK FH312; FH11327; MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition. |
|
| DC8186 | Bexagliflozin3 Featured | Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. |
|
| DCAPI1078 | Bexarotene Featured | Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM)[1][2][3]. Bexarotene can be used for the research of cutaneous T-cell lymphoma. |
|
| DC8786 | NVP-BEZ235 Tosylate Featured | BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively, and also inhibits ATR with IC50 of 21 nM. |
|
| DC3136 | NVP-BEZ235 Featured | BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively, and also inhibits ATR with IC50 of 21 nM. |
|
| DC9088 | Bezafibrate | Bezafibrate(BM15075) is the first clinically tested dual and pan-PPAR co-agonism. |
|
| DC12131 | BF-227(E/Z) Featured | BF 227 is a candidate for an amyloid imaging probe for PET, with a Ki of 4.3 nM for Aβ1-42 fibrils. |
|
| DC20797 | BF 844 | BF 844 (BioFocus 844) is a small molecules capable of stabilizing mutant USH3 mutation CLRN1(N48K). |
|
| DC12136 | BF-168 | BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42. |
|
| DC20767 | BF738735 | BF738735 is a novel, broad-spectrum inhibitor of enterovirus replication (EC50=4-71 nM) that specifically targets host cell factor PI4KIIIβ with IC50 of 5.7 nM, 300-fold less potent for PI4KIIIα (IC50=1.7 uM). |
|
| DC9956 | BFH772 Featured | BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. |
|
| DC8310 | BG-45 Featured | BG45 is an HDAC class I inhibitor with selectivity for HDAC3 (IC50 = 289 nM). It inhibits HDAC1, HDAC2, and HDAC6 with greatly reduced potency (IC50s = 2, 2.2, and >20 µM, respectively). |
|
| DC10335 | BGB-3111 | BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. |
|
| DC22196 | BGC20-1531 | BGC20-1531 (PGN-1531, AP 1531) is a potent, selective prostanoid EP receptor EP antagonist, exhibits high affinity at recombinant human EP4 receptors expressed in cell lines (pKB=7.6) and native EP4 receptors in human cerebral and meningeal artery (pKB=7. |
|
| DC10059 | BGG463 Featured | BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively. |
|
| DC5194 | NVP-BGJ398(Infigratinib) Featured | BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2. |
|
| DC8571 | BGP-15 Featured | BGP-15 is a PARP inhibitor and insulin sensitizer. |
|
| DC9695 | BH3I-1 Featured | BH3I-1 is a cell permeable BH3 mimetic that binds to Bcl-xL. BH3I-1 is an inhibitor of Bcl-xL. |
|
| DC21359 | BHC | BHC (Myosin inhibitor BHC) is a small-molecule screen of skeletal muscle myosin inhibitor that suppresses movements without affecting membrane currents. |
|
| DC23177 | BHPI | BHPI is a potent, noncompetitive small molecule ERα inhibitor (biomodulator) that selectively blocks proliferation of drug-resistant ERα-positive breast and ovarian cancer cells. |
|
| DC9426 | B-HT 920 | B-HT 920(Talipexole 2Hcl) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity. |
|
| DC21546 | BI-1467335 HCl Featured | BI 1467335 (PXS-4728A, PXS-4728) is a potent, selective, orally active SSAO/VAP-1 (AOC3) inhibitor with IC50 of 5 nM; displays >500-fold selective for VAP-1/SSAO over all the related human amine oxidases; diminishes leukocyte rolling and adherence induced by CXCL1/KC, also inhibits the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis. |
|
| DC22021 | BI 167107 Featured | BI 167107 is a highly potent agonist of the β2 adrenergic receptor (β2AR) and β1AR (IC50=3.2 nM) and shows some activity as α1A antagonist (IC50 = 32 nM). |
|
| DC20776 | BI 187004 | BI 187004 (VTP-34072) is a novel potent, selective 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor intended to treat type 2 diabetes mellitus (T2D).. |
|
| DC20778 | BI 207524 | BI 207524 is a potent inhibitor of HCV thumb pocket 1 NS5B inhibitor with IC50 of 84 nM, inhibits Gt 1a/1b replicons with EC50 of 29/11 nM.. |
|
| DC11389 | BI 409306 Featured | BI 409306 is an inhibitor of phosphodisterase 9A（PDE9A）. |
|
| DC22026 | BI 665915 | BI 665915 is a highly potent, selective, orally active 5-lipoxygenase-activating protein (FLAP) inhibitor with binding IC50 of 1.7 nM. |
|
